Literature DB >> 30497199

Efficacy of limited hippocampal radiofrequency thermocoagulation for mesial temporal lobe epilepsy.

Ching-Yi Lee1, Han-Tao Li2, Tony Wu2, Mei-Yun Cheng2, Siew-Na Lim2, Shih-Tseng Lee1.   

Abstract

OBJECTIVE: Radiofrequency thermocoagulation (RFTC), which has been developed for drug-resistant epilepsy patients, involves less brain tissue loss due to surgery, fewer surgical adverse effects, and generally good seizure control. This study demonstrates the effectiveness of RFTC performed at limited hippocampal locations.
METHODS: Daily seizure diaries were prospectively maintained for at least 6 months by 9 patients (ages 30-59 years) with drug-resistant mesial temporal lobe epilepsy (MTLE) before treatment with RFTC. The limited target for stereotactic RFTC was chosen based on intraoperative electroencephalography (EEG) recording and was initially tested with a Radionics electrode at a low temperature, 45°C, for 60 seconds. The therapeutic RFTC heating parameters were 78°C-80°C for 90 seconds. All patients who received the RFTC treatment underwent both MRI and EEG recording immediately postoperatively and at the 3-month follow-up. Monthly outpatient clinic visits were arranged over 6 months to document seizure frequency and severity to clarify the changes noted in imaging studies and EEG patterns.
RESULTS: Two patients were excluded from our analysis because one had undergone multiple seizure surgeries and the other had a poor recording of seizure frequency, before the RFTC surgery. Five and two patients underwent left-sided and right-sided RFTC, respectively. None of the patients had generalized tonic-clonic attacks postoperatively, and no adverse effects or complications occurred. According to MRI data, the effect of coagulation was limited to less than 1.0 cm in diameter and perifocal edema was also in limited range. The seizure frequency within 6 months decreased postoperatively with a mean reduction in seizures of 78% (range 36%-100%). Only two patients had a temporary increase in seizure frequency within 2 weeks of the surgery, and over 50% of all patients showed a decrease in average seizure frequency.
CONCLUSIONS: The study results confirm that limited RFTC provides a more effective surgery with similar seizure control but fewer complications than resective surgery for drug-resistant MTLE patients.

Entities:  

Keywords:  AED = antiepileptic drug; CPS = complex partial seizure; DG = dentate gyrus; EEG = electroencephalography; GTC = generalized tonic-clonic; MTLE = mesial temporal lobe epilepsy; RFTC = radiofrequency thermocoagulation; SEEG = stereo-EEG; drug-resistant mesial temporal lobe epilepsy; minimally invasive epilepsy surgery; radiofrequency thermocoagulation; stereoelectroencephalography

Mesh:

Year:  2018        PMID: 30497199     DOI: 10.3171/2018.4.JNS184

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Stereo-crossed ablation guided by stereoelectroencephalography for epilepsy: comprehensive coagulations via a network of multi-electrodes.

Authors:  Peng-Hu Wei; Xiao-Tong Fan; Yi-He Wang; Chao Lu; Si-Qi Ou; Fei Meng; Mu-Yang Li; Hua-Qiang Zhang; Si-Chang Chen; Yang An; Yan-Feng Yang; Lian-Kun Ren; Yong-Zhi Shan; Guo-Guang Zhao
Journal:  Ther Adv Neurol Disord       Date:  2020-06-09       Impact factor: 6.570

2.  Robot-Assisted Radiofrequency Ablation Combined with Thermodynamic Simulation for Epilepsy Reoperations.

Authors:  Yu-Chi Wang; Mei-Yun Cheng; Po-Cheng Hung; Cheng-Yen Kuo; Hsiang-Yao Hsieh; Kuang-Lin Lin; Po-Hsun Tu; Chieh-Tsai Wu; Peng-Wei Hsu; Kuo-Chen Wei; Chi-Cheng Chuang
Journal:  J Clin Med       Date:  2022-08-17       Impact factor: 4.964

3.  Stereotactic EEG-guided radiofrequency thermocoagulation versus anterior temporal lobectomy for mesial temporal lobe epilepsy with hippocampal sclerosis: study protocol for a randomised controlled trial.

Authors:  Yi-He Wang; Si-Chang Chen; Peng-Hu Wei; Kun Yang; Xiao-Tong Fan; Fei Meng; Jia-Lin Du; Lian-Kun Ren; Yong-Zhi Shan; Guo-Guang Zhao
Journal:  Trials       Date:  2021-06-29       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.